Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells
Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Amiri, Hamed [verfasserIn] Javid, Hossein [verfasserIn] Einafshar, Elham [verfasserIn] Ghavidel, Farideh [verfasserIn] Rajabian, Arezoo [verfasserIn] Hashemy, Seyed Isaac [verfasserIn] Hosseini, Hossein [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2024 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| Übergeordnetes Werk: |
Enthalten in: BioNanoScience - Springer US, 2011, 14(2024), 2 vom: 27. Feb., Seite 988-998 |
|---|---|
| Übergeordnetes Werk: |
volume:14 ; year:2024 ; number:2 ; day:27 ; month:02 ; pages:988-998 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12668-024-01345-9 |
|---|
| Katalog-ID: |
SPR056513186 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR056513186 | ||
| 003 | DE-627 | ||
| 005 | 20240709064739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240709s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12668-024-01345-9 |2 doi | |
| 035 | |a (DE-627)SPR056513186 | ||
| 035 | |a (SPR)s12668-024-01345-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 530 |q VZ |
| 100 | 1 | |a Amiri, Hamed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. | ||
| 650 | 4 | |a Prostate cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Resveratrol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nanoparticles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a PLGA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chitosan |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Folic acid |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Javid, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Einafshar, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Ghavidel, Farideh |e verfasserin |4 aut | |
| 700 | 1 | |a Rajabian, Arezoo |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemy, Seyed Isaac |e verfasserin |0 (orcid)0000-0002-1323-5250 |4 aut | |
| 700 | 1 | |a Hosseini, Hossein |e verfasserin |0 (orcid)0000-0003-4859-7291 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioNanoScience |d Springer US, 2011 |g 14(2024), 2 vom: 27. Feb., Seite 988-998 |w (DE-627)657588601 |w (DE-600)2606470-4 |x 2191-1649 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:27 |g month:02 |g pages:988-998 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12668-024-01345-9 |m X:SPRINGER |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a SYSFLAG_0 | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2056 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 27 |c 02 |h 988-998 | ||
| author_variant |
h a ha h j hj e e ee f g fg a r ar s i h si sih h h hh |
|---|---|
| matchkey_str |
article:21911649:2024----::eeomnadvlainflaaoatcesraemdfewtcioaflccdoipoedlvr |
| hierarchy_sort_str |
2024 |
| publishDate |
2024 |
| allfields |
10.1007/s12668-024-01345-9 doi (DE-627)SPR056513186 (SPR)s12668-024-01345-9-e DE-627 ger DE-627 rakwb eng 530 VZ Amiri, Hamed verfasserin aut Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. Prostate cancer (dpeaa)DE-He213 Resveratrol (dpeaa)DE-He213 Nanoparticles (dpeaa)DE-He213 PLGA (dpeaa)DE-He213 Chitosan (dpeaa)DE-He213 Folic acid (dpeaa)DE-He213 Javid, Hossein verfasserin aut Einafshar, Elham verfasserin aut Ghavidel, Farideh verfasserin aut Rajabian, Arezoo verfasserin aut Hashemy, Seyed Isaac verfasserin (orcid)0000-0002-1323-5250 aut Hosseini, Hossein verfasserin (orcid)0000-0003-4859-7291 aut Enthalten in BioNanoScience Springer US, 2011 14(2024), 2 vom: 27. Feb., Seite 988-998 (DE-627)657588601 (DE-600)2606470-4 2191-1649 nnns volume:14 year:2024 number:2 day:27 month:02 pages:988-998 https://dx.doi.org/10.1007/s12668-024-01345-9 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 14 2024 2 27 02 988-998 |
| spelling |
10.1007/s12668-024-01345-9 doi (DE-627)SPR056513186 (SPR)s12668-024-01345-9-e DE-627 ger DE-627 rakwb eng 530 VZ Amiri, Hamed verfasserin aut Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. Prostate cancer (dpeaa)DE-He213 Resveratrol (dpeaa)DE-He213 Nanoparticles (dpeaa)DE-He213 PLGA (dpeaa)DE-He213 Chitosan (dpeaa)DE-He213 Folic acid (dpeaa)DE-He213 Javid, Hossein verfasserin aut Einafshar, Elham verfasserin aut Ghavidel, Farideh verfasserin aut Rajabian, Arezoo verfasserin aut Hashemy, Seyed Isaac verfasserin (orcid)0000-0002-1323-5250 aut Hosseini, Hossein verfasserin (orcid)0000-0003-4859-7291 aut Enthalten in BioNanoScience Springer US, 2011 14(2024), 2 vom: 27. Feb., Seite 988-998 (DE-627)657588601 (DE-600)2606470-4 2191-1649 nnns volume:14 year:2024 number:2 day:27 month:02 pages:988-998 https://dx.doi.org/10.1007/s12668-024-01345-9 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 14 2024 2 27 02 988-998 |
| allfields_unstemmed |
10.1007/s12668-024-01345-9 doi (DE-627)SPR056513186 (SPR)s12668-024-01345-9-e DE-627 ger DE-627 rakwb eng 530 VZ Amiri, Hamed verfasserin aut Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. Prostate cancer (dpeaa)DE-He213 Resveratrol (dpeaa)DE-He213 Nanoparticles (dpeaa)DE-He213 PLGA (dpeaa)DE-He213 Chitosan (dpeaa)DE-He213 Folic acid (dpeaa)DE-He213 Javid, Hossein verfasserin aut Einafshar, Elham verfasserin aut Ghavidel, Farideh verfasserin aut Rajabian, Arezoo verfasserin aut Hashemy, Seyed Isaac verfasserin (orcid)0000-0002-1323-5250 aut Hosseini, Hossein verfasserin (orcid)0000-0003-4859-7291 aut Enthalten in BioNanoScience Springer US, 2011 14(2024), 2 vom: 27. Feb., Seite 988-998 (DE-627)657588601 (DE-600)2606470-4 2191-1649 nnns volume:14 year:2024 number:2 day:27 month:02 pages:988-998 https://dx.doi.org/10.1007/s12668-024-01345-9 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 14 2024 2 27 02 988-998 |
| allfieldsGer |
10.1007/s12668-024-01345-9 doi (DE-627)SPR056513186 (SPR)s12668-024-01345-9-e DE-627 ger DE-627 rakwb eng 530 VZ Amiri, Hamed verfasserin aut Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. Prostate cancer (dpeaa)DE-He213 Resveratrol (dpeaa)DE-He213 Nanoparticles (dpeaa)DE-He213 PLGA (dpeaa)DE-He213 Chitosan (dpeaa)DE-He213 Folic acid (dpeaa)DE-He213 Javid, Hossein verfasserin aut Einafshar, Elham verfasserin aut Ghavidel, Farideh verfasserin aut Rajabian, Arezoo verfasserin aut Hashemy, Seyed Isaac verfasserin (orcid)0000-0002-1323-5250 aut Hosseini, Hossein verfasserin (orcid)0000-0003-4859-7291 aut Enthalten in BioNanoScience Springer US, 2011 14(2024), 2 vom: 27. Feb., Seite 988-998 (DE-627)657588601 (DE-600)2606470-4 2191-1649 nnns volume:14 year:2024 number:2 day:27 month:02 pages:988-998 https://dx.doi.org/10.1007/s12668-024-01345-9 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 14 2024 2 27 02 988-998 |
| allfieldsSound |
10.1007/s12668-024-01345-9 doi (DE-627)SPR056513186 (SPR)s12668-024-01345-9-e DE-627 ger DE-627 rakwb eng 530 VZ Amiri, Hamed verfasserin aut Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. Prostate cancer (dpeaa)DE-He213 Resveratrol (dpeaa)DE-He213 Nanoparticles (dpeaa)DE-He213 PLGA (dpeaa)DE-He213 Chitosan (dpeaa)DE-He213 Folic acid (dpeaa)DE-He213 Javid, Hossein verfasserin aut Einafshar, Elham verfasserin aut Ghavidel, Farideh verfasserin aut Rajabian, Arezoo verfasserin aut Hashemy, Seyed Isaac verfasserin (orcid)0000-0002-1323-5250 aut Hosseini, Hossein verfasserin (orcid)0000-0003-4859-7291 aut Enthalten in BioNanoScience Springer US, 2011 14(2024), 2 vom: 27. Feb., Seite 988-998 (DE-627)657588601 (DE-600)2606470-4 2191-1649 nnns volume:14 year:2024 number:2 day:27 month:02 pages:988-998 https://dx.doi.org/10.1007/s12668-024-01345-9 X:SPRINGER Resolving-System lizenzpflichtig Volltext SYSFLAG_0 GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 14 2024 2 27 02 988-998 |
| language |
English |
| source |
Enthalten in BioNanoScience 14(2024), 2 vom: 27. Feb., Seite 988-998 volume:14 year:2024 number:2 day:27 month:02 pages:988-998 |
| sourceStr |
Enthalten in BioNanoScience 14(2024), 2 vom: 27. Feb., Seite 988-998 volume:14 year:2024 number:2 day:27 month:02 pages:988-998 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Prostate cancer Resveratrol Nanoparticles PLGA Chitosan Folic acid |
| dewey-raw |
530 |
| isfreeaccess_bool |
false |
| container_title |
BioNanoScience |
| authorswithroles_txt_mv |
Amiri, Hamed @@aut@@ Javid, Hossein @@aut@@ Einafshar, Elham @@aut@@ Ghavidel, Farideh @@aut@@ Rajabian, Arezoo @@aut@@ Hashemy, Seyed Isaac @@aut@@ Hosseini, Hossein @@aut@@ |
| publishDateDaySort_date |
2024-02-27T00:00:00Z |
| hierarchy_top_id |
657588601 |
| dewey-sort |
3530 |
| id |
SPR056513186 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR056513186</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240709064739.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240709s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12668-024-01345-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR056513186</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12668-024-01345-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amiri, Hamed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostate cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Resveratrol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanoparticles</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PLGA</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Folic acid</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Javid, Hossein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Einafshar, Elham</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghavidel, Farideh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajabian, Arezoo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hashemy, Seyed Isaac</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-1323-5250</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hosseini, Hossein</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-4859-7291</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioNanoScience</subfield><subfield code="d">Springer US, 2011</subfield><subfield code="g">14(2024), 2 vom: 27. Feb., Seite 988-998</subfield><subfield code="w">(DE-627)657588601</subfield><subfield code="w">(DE-600)2606470-4</subfield><subfield code="x">2191-1649</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:2</subfield><subfield code="g">day:27</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:988-998</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12668-024-01345-9</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2024</subfield><subfield code="e">2</subfield><subfield code="b">27</subfield><subfield code="c">02</subfield><subfield code="h">988-998</subfield></datafield></record></collection>
|
| author |
Amiri, Hamed |
| spellingShingle |
Amiri, Hamed ddc 530 misc Prostate cancer misc Resveratrol misc Nanoparticles misc PLGA misc Chitosan misc Folic acid Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells |
| authorStr |
Amiri, Hamed |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)657588601 |
| format |
electronic Article |
| dewey-ones |
530 - Physics |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2191-1649 |
| topic_title |
530 VZ Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells Prostate cancer (dpeaa)DE-He213 Resveratrol (dpeaa)DE-He213 Nanoparticles (dpeaa)DE-He213 PLGA (dpeaa)DE-He213 Chitosan (dpeaa)DE-He213 Folic acid (dpeaa)DE-He213 |
| topic |
ddc 530 misc Prostate cancer misc Resveratrol misc Nanoparticles misc PLGA misc Chitosan misc Folic acid |
| topic_unstemmed |
ddc 530 misc Prostate cancer misc Resveratrol misc Nanoparticles misc PLGA misc Chitosan misc Folic acid |
| topic_browse |
ddc 530 misc Prostate cancer misc Resveratrol misc Nanoparticles misc PLGA misc Chitosan misc Folic acid |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
BioNanoScience |
| hierarchy_parent_id |
657588601 |
| dewey-tens |
530 - Physics |
| hierarchy_top_title |
BioNanoScience |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)657588601 (DE-600)2606470-4 |
| title |
Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells |
| ctrlnum |
(DE-627)SPR056513186 (SPR)s12668-024-01345-9-e |
| title_full |
Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells |
| author_sort |
Amiri, Hamed |
| journal |
BioNanoScience |
| journalStr |
BioNanoScience |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2024 |
| contenttype_str_mv |
txt |
| container_start_page |
988 |
| author_browse |
Amiri, Hamed Javid, Hossein Einafshar, Elham Ghavidel, Farideh Rajabian, Arezoo Hashemy, Seyed Isaac Hosseini, Hossein |
| container_volume |
14 |
| class |
530 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Amiri, Hamed |
| doi_str_mv |
10.1007/s12668-024-01345-9 |
| normlink |
(ORCID)0000-0002-1323-5250 (ORCID)0000-0003-4859-7291 |
| normlink_prefix_str_mv |
(orcid)0000-0002-1323-5250 (orcid)0000-0003-4859-7291 |
| dewey-full |
530 |
| author2-role |
verfasserin |
| title_sort |
development and evaluation of plga nanoparticles surfaced modified with chitosan-folic acid for improved delivery of resveratrol to prostate cancer cells |
| title_auth |
Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells |
| abstract |
Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstractGer |
Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| abstract_unstemmed |
Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| collection_details |
SYSFLAG_0 GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
2 |
| title_short |
Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells |
| url |
https://dx.doi.org/10.1007/s12668-024-01345-9 |
| remote_bool |
true |
| author2 |
Javid, Hossein Einafshar, Elham Ghavidel, Farideh Rajabian, Arezoo Hashemy, Seyed Isaac Hosseini, Hossein |
| author2Str |
Javid, Hossein Einafshar, Elham Ghavidel, Farideh Rajabian, Arezoo Hashemy, Seyed Isaac Hosseini, Hossein |
| ppnlink |
657588601 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12668-024-01345-9 |
| up_date |
2024-07-10T07:13:03.880Z |
| _version_ |
1804175235010789376 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR056513186</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240709064739.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240709s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12668-024-01345-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR056513186</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12668-024-01345-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Amiri, Hamed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Development and Evaluation of PLGA Nanoparticles Surfaced Modified with Chitosan-Folic Acid for Improved Delivery of Resveratrol to Prostate Cancer Cells</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Resveratrol is an active ingredient in grapes with various biological and pharmacological activities, including anti-inflammatory, antioxidant, antiviral, phyto-estrogenic, antitumor, and anti-metastatic properties. However, its clinical applications are limited due to its photo-instability, low chemical stability, and poor bioavailability. This study aimed to address these limitations by developing resveratrol-loaded PLGA nanoparticles, modified with chitosan-folate (Res-PCF-NPs) and evaluating their anticancer effects against prostate cancer cells. The Res-PCF-NPs were characterized using dynamic light scattering (DLS), Fourier transform infrared spectroscopy (FTIR), zeta potential (ξ–potential), and field emission scanning electron microscopy (FESEM) analyses. The biological experiments included resazurin assay and real-time PCR analysis performed to determine the cytotoxicity and apoptosis effects of Res-PCF-NPs on PC-3 prostate cancer cells. Additionally, the oxidant-antioxidant potential of the nanoparticles was examined by measuring the activity of antioxidant enzymes and conducting the DCF-DA assay. The resazurin assay demonstrated significant cytotoxic activity of Res-PCF-NPs against PC-3 cells, with an IC50 of 83 and 51 μg/mL at 24 and 48 h, respectively. Real-time PCR analysis confirmed the effect of Res-PCF-NPs on inducing cell death in PC-3 cells by modulating the expression of apoptosis-related genes. Also, our data suggests that the anticancer effect of Res-PCF-NPs is mediated through the induction of oxidative stress in PC-3 cells. Overall, our findings highlight the potential use of Res-PCF-NPs as an effective anticancer treatment for human prostate cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostate cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Resveratrol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nanoparticles</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PLGA</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chitosan</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Folic acid</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Javid, Hossein</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Einafshar, Elham</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghavidel, Farideh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajabian, Arezoo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hashemy, Seyed Isaac</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-1323-5250</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hosseini, Hossein</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-4859-7291</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BioNanoScience</subfield><subfield code="d">Springer US, 2011</subfield><subfield code="g">14(2024), 2 vom: 27. Feb., Seite 988-998</subfield><subfield code="w">(DE-627)657588601</subfield><subfield code="w">(DE-600)2606470-4</subfield><subfield code="x">2191-1649</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:2</subfield><subfield code="g">day:27</subfield><subfield code="g">month:02</subfield><subfield code="g">pages:988-998</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12668-024-01345-9</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2024</subfield><subfield code="e">2</subfield><subfield code="b">27</subfield><subfield code="c">02</subfield><subfield code="h">988-998</subfield></datafield></record></collection>
|
| score |
7.4012194 |